6 research outputs found
Additional file1: of Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma
Figure S1. Quantification of PKM1 and PKM2 staining intensities shown as percent of tissue cores scored in 16 normal human skeletal muscle samples (A) and 48 primary human rhabdomyosarcomas (B). Score 0 = no staining, Score 1 = weak, Score 2 = positive, or Score 3 = strong. (C) Representative images of IHC for PKM1 and PKM2 in KP mouse sarcoma tissue. Corresponding H&E images are shown. Scale bars, 20 μm. (JPG 1314 kb
Additional file 4: of Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma
Table S1. Raw data for LC-MS metabolomics on KP M2+/+ and KP M2-/- sarcomas. Related to Fig. 5. This table contains all the LC-MS metabolomics data. Includes normalization and statistical analysis for each measured metabolite. (XLSX 140 kb
Additional file 3: of Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma
Figure S3. (A) Representative images of IF for tdTomato, PKM1 or PKM2, and EdU on KP M2 +/+ or KP M2 −/− sarcoma cell lines. (B) Cumulative populaion doublings of KP M2 +/+ or KP M2 −/− sarcoma cell lines, n = 3 KP M2 +/+ cell lines and n = 4 KP M2 −/− cell lines. (C) Sarcoma weight in grams. (JPG 2694 kb
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
Human pancreatic ductal adenocarcinoma
(PDAC) contains a distinctively
dense stroma that limits the accessibility of anticancer drugs, contributing
to its poor overall prognosis. Nanoparticles can enhance drug delivery
and retention in pancreatic tumors and have been utilized clinically
for their treatment. In preclinical studies, various mouse models
differentially recapitulate the microenvironmental features of human
PDAC. Here, we demonstrate that through utilization of different organic
cosolvents and by doping of a homopolymer of polyÂ(ε-caprolactone),
a diblock copolymer composition of polyÂ(ethylene oxide)-<i>block</i>-polyÂ(ε-caprolactone) may be utilized to generate biodegradable
and nanoscale micelles with different physical properties. Noninvasive
optical imaging was employed to examine the pharmacology and biodistribution
of these various nanoparticle formulations in both allografted and
autochthonous mouse models of PDAC. In contrast to the results reported
with transplanted tumors, spherical micelles as large as 300 nm in
diameter were found to extravasate in the autochthonous model, reaching
a distance of approximately 20 μm from the nearest tumor cell
clusters. A lipophilic platinumÂ(IV) prodrug of oxaliplatin was further
able to achieve a ∼7-fold higher peak accumulation and a ∼50-fold
increase in its retention half-life in pancreatic tumors when delivered
with 100 nm long worm-like micelles as when compared to the free drug
formulation of oxaliplatin. Through further engineering of nanoparticle
properties, as well as by widespread adoption of the autochthonous
tumor model for preclinical testing, future therapeutic formulations
may further enhance the targeting and penetration of anticancer agents
to improve survival outcomes in PDAC
Characterization of distinct peptides identified from mouse plasma reference sets
The histogram of peptide length of unique sequences in mouse PeptideAtlas (blue) is overlaid on an tryptic digest of the IPI mouse database (black).<p><b>Copyright information:</b></p><p>Taken from "A mouse plasma peptide atlas as a resource for disease proteomics"</p><p>http://genomebiology.com/2008/9/6/R93</p><p>Genome Biology 2008;9(6):R93-R93.</p><p>Published online 3 Jun 2008</p><p>PMCID:PMC2481425.</p><p></p
Genomic mapping of mouse peptide LLEAQIATGGIIDPK using UCSC Blast program
Mouse splice variant M13C2563_1_s386_e8960_1_rf2_c1_n0 was identified with 13 distinct peptides. Twelve peptides matched a predicted mouse protein similar to desmoplakin using a homolog search against the NCBI NR database. However, all 13 peptides were homologous to the human desmoplakin sequence. Of note, mouse peptide LLEAQIATGGIIDPK aligns to the coding sequence of human desmoplakin, but not to the annotated mouse desmoplakin gene.<p><b>Copyright information:</b></p><p>Taken from "A mouse plasma peptide atlas as a resource for disease proteomics"</p><p>http://genomebiology.com/2008/9/6/R93</p><p>Genome Biology 2008;9(6):R93-R93.</p><p>Published online 3 Jun 2008</p><p>PMCID:PMC2481425.</p><p></p